Moderna announces test results for skin cancer vaccine


Melanoma Monday tips to prevent skin cancer


Skin cancer screening, safe sun exposure promoted on Melanoma Monday

03:00

A vaccine shows promising results in treating the most deadly form of skin cancer, Moderna and Merck announced on Thursday.

Those with severe melanomas who received the vaccine and Merck’s cancer drug Keytruda were 49% less likely to die or have their cancer come back after three years than those who were given only Keytruda, the biotech companies said in a news release

The companies have begun Phase 3 trials of mRNA-4157 with Keytruda, given a breakthrough therapy designation by the Food and Drug Administration earlier this year. The designation is meant to expedite the development and review of drugs meant to treat life-threatening diseases.

“We look forward to sharing these data with people impacted by the disease and the broader scientific community,” Kyle Holen, M.D., Moderna’s senior vice president and head of development, therapeutics and oncology, stated.

The results are a vindication of sorts for Moderna’s strategy to develop new uses for messenger RNA technology used in its COVID-19 vaccine. Cambridge, Massachusetts-based Moderna said in November it anticipates a steep decline in revenue next year, fueling worries about its capacity to finance multiple product launches planned for 2024 and 2025.


New study finds mRNA vaccine helps battle against melanoma

04:40

Skin cancer is the most common form of cancer, with melanoma accounting for only about 1% of skin cancer cases in the U.S. That said, it causes a large majority of skin cancer deaths, according to the American Cancer Society. It estimates about 97,610 new melanomas will be diagnosed in the U.S. this year, resulting in 7,990 deaths.

Moderna’s stock has cratered this year, falling 50%. On Thursday, its shares shot up 12% in mid-day trading to $87.93. 

Rahway, New Jersey-based Merck shares treaded water, down 0.2% at $106.16.


Leave a Reply

Your email address will not be published. Required fields are marked *